Mutations in the PIK3CA gene are a key driver of breast cancer and are present in 35–40% of hormone receptor–positive breast ...

A new three-drug combination could help women with a common form of aggressive breast cancer live longer, research suggests.

Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the ...

Panelists discuss how to communicate genomic testing results to patients and make shared treatment decisions, particularly when multiple targeted therapy options are available for patients with ESR1 ...

The Phase III trial showed that the new targeted therapy, inavolisib (Itovebi), provides significant survival benefits for ...

A novel triple therapy for advanced breast cancer significantly slows disease progression and extends patient survival, ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive ...

The lead author said the study also showed the inavolisib-based therapy "more than doubled the time before their cancer progressed or worsened".

EMA committee recommends approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer: Basel Monday, May 26, 2025, 12:00 Hrs [IST] Roche an ...

The treatment could also delay the need for gruelling chemotherapy, according to the trial. | ITV National News ...